Eledon Pharmaceuticals
ELDN
30 hedge funds and large institutions have $14.7M invested in Eledon Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
467% more call options, than puts
Call options by funds: $17K | Put options by funds: $3K
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
7% more funds holding
Funds holding: 28 → 30 (+2)
3% more capital invested
Capital invested by funds: $14.3M → $14.7M (+$389K)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.08% less ownership
Funds ownership: 45.43% → 45.35% (-0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$82.6K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$40.2K |
| 3 |
V
Veritable
Wilmington,
Delaware
|
+$34.9K |
| 4 |
Millennium Management
New York
|
+$33.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$154K |
| 2 |
SFG
SVB Financial Group
Dallas,
Texas
|
-$36.6K |
| 3 |
Two Sigma Investments
New York
|
-$10.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.47K |
| 5 |
Rockefeller Capital Management
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAS
26
Ameritas Advisory Services
Lincoln,
Nebraska
| $2.27K | +$2.68K | +1,000 | New |
|
27
Group One Trading
Chicago,
Illinois
| $1.42K | +$1.61K | +600 | New |
|
|
28
UBS Group
Zurich,
Switzerland
| $1.08K | -$9.47K | -3,536 | -89% |
|
29
Wells Fargo
San Francisco,
California
| $203 | +$5 | +2 | +2% |
|
|
EP
30
Eversept Partners
New York
| – | -$154K | -67,743 | Closed |
|
|
31
Rockefeller Capital Management
New York
| – | -$3K | -1,666 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$32 | -14 | Closed |
|
|
IA
33
IFP Advisors
Tampa,
Florida
| – | -$1K | -1 | Closed |
|
34
Morgan Stanley
New York
| – | -$2 | -1 | Closed |
|
35
Simplex Trading
Chicago,
Illinois
| – | +$185 | +69 | New |
|
ELDN Hedge Fund Activity: Q1 2023 in Review
30 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2023, worth a combined $14.7M — up 2.7% from $14.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ELDN positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $82.6K. The largest seller was Eversept Partners, exiting entirely with an estimated $154K sold.
- 30 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $14.7M of Eledon Pharmaceuticals stock for Q1 2023, up 2.7% quarter-over-quarter.
- 7 funds opened new Eledon Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of +2 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2023 was Citadel Advisors, an estimated $82.6K added.
- The largest Eledon Pharmaceuticals seller in Q1 2023 was Eversept Partners, an estimated $154K sold.
Based on aggregated 13F filings for Q1 2023.